

City & County of San Francisco v. Purdue Pharma, et al.

Case No. 3:18-CV-07591-CRB

Exhibits Introduced by Defendants on May 9, 2022

Type Exhibit	Exhibit Number	TREX List Description	Party that Introduced Exhibit
Court Exhibit	Allergan Defendants Court Exhibit 00001	Demonstrative slides used for Allergan Defendants' Cross-Examination of Dr. Anna Lembke	Allergan Defendants
Court Exhibit	TCA Defendants Court Exhibit 00001	Demonstrative slides used for Teva, Cephalon, and Actavis Generic Defendants' Cross-Examination of Dr. Anna Lembke	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	AL-SF-00068	Letter from C. Wright, MD to G. Wagner re New Drug Application	Allergan Defendants
Trial Exhibit	AL-SF-00339	KADIAN CII (morphine sulfate extended-release) Capsules label (Revised March 2007)	Allergan Defendants
Trial Exhibit	AL-SF-01324	NORCO 5/325 Hydrocodone Bitartrate and Acetaminophen Tablets USP 5 mg/325 mg, revised 04/03, Watson Pharma, Inc.	Allergan Defendants
Trial Exhibit	CE-SF-00963	12/05/2007 Fentora Labeling Supplement	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	CE-SF-00966	11/04/1998 Actiq Label	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	CE-SF-00985	Fentora Learning System – Risk Minimization Plan	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	DEF-MDL-05612	FDA: Abuse-Deterrent Opioid Analgesics	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	DEF-MDL-05666	03/21/2005 State Attorneys General Comment on Dispensing of Controlled Substances	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	DEF-MDL-06142	APS Definitions Related to the Use of Opioids for the Treatment of Pain	Teva, Cephalon, and Actavis Generics Defendants

Type Exhibit	Exhibit Number	TREX List Description	Party that Introduced Exhibit
Trial Exhibit	DEF-MDL-09038	Medical Board of California Guidelines for Prescribing Controlled Substances	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	DEF-MDL-10441	Abuse-Deterrent Opioids – Evaluation and Labeling (U.S. DHHS)	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	DEF-MDL-10700	Weighing the Risks and Benefits of Chronic Opioid Therapy (Lembke et al.)	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	DEF-MDL-12927	FDA: A Guide to Safe Use of Pain Medicine	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	DEF-MDL-15280	Pain and Disability: Clinical, Behavioral, and Public Policy Perspectives	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	DEF-MDL-15455	VA/DoD Clinical Practice Guide – Management of Opioid Therapy for Chronic Pain	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	DEF-MDL-15457	NIDA Research Report – Prescription Drugs Abuse and Addiction	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	DEF-MDL-15461	NDIC Information Bulletin – OxyContin Diversion and Abuse	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	DEF-MDL-15949	FDA: Abuse-Deterrent Opioid Analgesics	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	TE-SF-00689	SAMSHA Substance Abuse Treatment Advisory	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	TE-SF-02618	FDA: Understanding Unapproved Use of Approved	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	TE-SF-02751	New Approaches to the Treatment of Chronic Pain	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	TE-SF-02756	Physician’s Manual: An Information Outline of the CSA	Teva, Cephalon, and Actavis Generics Defendants

Type Exhibit	Exhibit Number	TREX List Description	Party that Introduced Exhibit
Trial Exhibit	TE-SF-02764	VA/DoD Clinical Practice Guideline for the Management of Opioid Therapy for Chronic Pain	Teva, Cephalon, and Actavis Generics Defendants
Trial Exhibit	TE-SF-02798	State Board of Pharmacy – Pain Management	Teva, Cephalon, and Actavis Generics Defendants